Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin in Low/Int-1 Risk MDS
NCT00542828Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2007
- Primary completion
- May 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of antithymocyte globulin in myelodysplastic syndrome (MDS), sponsored by Sanofi. Started Oct 2007; status: terminated.
02
Drugs
antithymocyte globulin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00542828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542828.